Those successes, along with recent approvals for new treatments and expanding sales in developing countries, have supercharged the business of turning human blood into medications. In the five years to 2027, the market for plasma-derived medicinal products will climb 38%, to almost $46 billion, according to market analysis firm BCC Research.